Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Changing the Paradigm: Controlled Hypothermia for Basal Cell Skin Cancer Treatment
Description
The speaker describes a new, non-surgical approach for treating basal cell skin cancer using controlled hypothermia rather than excision, radiation, or destructive cautery. The method uses a tightly monitored Arrhenius-based thermal dose, typically around 53–55 degrees Celsius for 60 seconds, delivered with a long-pulse 1064 laser and guided by temperature monitoring, FLIR imaging, and OCT to identify tumor margins and control treatment precisely. The goal is to induce apoptosis, not acute necrosis or charring, while preserving the tissue scaffold, extracellular matrix, vasculature, and basement membrane so the skin can repopulate more normally with less scarring and ulceration. The speaker presents examples showing post-treatment lilac-gray skin changes, temporary inflammation, and tumor-free follow-up at three months in many cases, with about 90% histologic clearance, while noting that inconsistent heating can lead to recurrence. The talk emphasizes that this is a promising option for patients, especially older individuals who want alternatives to surgery, and concludes by highlighting ongoing development of more precise robotic dosing technology and thanking collaborators.
View moreConclusions
- Arrhenius-controlled hyperthermia appears to be a feasible non-surgical treatment for basal cell carcinoma that can achieve about 90% histologic clearance at three months.
- The treatment’s effectiveness depends on precise control of time-temperature dosing, with cumulative Arrhenius dose and the Ω = 1 threshold predicting tumor clearance.
- Unlike destructive thermal methods, this protocol aims to induce gradual apoptosis rather than acute necrosis or charring.
- Preserving the tissue scaffold and extracellular matrix may support recellularization, resulting in less fibrosis, scarring, and ulceration.
- OCT and AI-assisted mapping improve tumor margin identification and treatment targeting, helping make the heating more uniform and controlled.
- Inhomogeneous heating appears to contribute to recurrence, implying that better dose sensing and control are important for success.
- The post-treatment skin response includes a characteristic lilac-gray change and transient inflammation, followed by more normal-appearing healing over time.
- This approach may be especially attractive for patients who want a noninvasive alternative to surgery, particularly older patients with multiple prior skin cancers.
- Christopher B. Zachary MBBS FRCP, Professor and Chair Emeritus, Department of Dermatology, University of California Irvine.
- https://doi.org/10.1136/bcr-2021-248588#10.1136/bcr-2021-248588
- David A Norris et al., JID (2008) 128, 949–956, doi:10.1038/sj.jid.5701114#10.1038/sj.jid.5701114
- Ahmed K, Zaidi SF, Journal of Pakistan Medical Association, 2013;63(4):504
- 1064 nm Long-Pulsed Nd:YAG Laser Treatment of Basal Cell Carcinoma
- THERMAL DOSE REQUIREMENT FOR TISSUE EFFECT: EXPERIMENTAL AND CLINICAL FINDINGS#10.1117/12.476637
- Assessing the Outcomes of Focused Heating of the Skin by a Long-Pulsed 1064 nm Laser with an Integrated Scanner, Infrared Thermal Guidance, and Optical Coherence Tomography#10.1002/lsm.23377